Skip to main content
SpringerLink
Log in

Safety of Agents Used to Prevent Mother-to-Child Transmission of HIV

Is There Any Cause for Concern?

  • Leading Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Antiretroviral drugs have been used routinely to reduce the risk of mother-to-child transmission of HIV infection since 1994, following the AIDS Clinical Trials Group 076 trial, which demonstrated the efficacy of zidovudine in reducing the risk of in utero and intrapartum transmission. The use of antiretroviral drugs in pregnancy varies geographically, with widespread use of highly active antiretroviral therapy (HAART) in resource-rich settings for delaying maternal HIV disease progression as well as the prevention of mother-to-child transmission; however, in low- and middle-income settings, abbreviated prophylactic regimens focus on the perinatal period, with very limited access to HAART to date.

The potential risks associated with antiretroviral exposure for pregnant women, fetuses and infants depend on the duration of this exposure as well as the number and type of drugs. As the benefits of HAART regimens in reducing the risk of mother-to-child transmission and in delaying disease progression are so great, their widespread use has been accepted, despite the relative lack of safety data from human pregnancies.

Animal studies have suggested an increased risk of malformations associated with exposure to specific antiretroviral drugs, although evidence to support this from human studies is limited. Trials, cohorts and surveillance studies have shown no evidence of an increased risk of congenital malformations associated with in utero exposure to zidovudine, or other commonly used antiretroviral drugs, with an estimated 2–3% prevalence of birth defects (i.e. similar to that seen in the general population). Exposure to prophylactic zidovudine for prevention of mother-to-child transmission is associated with a usually mild and reversible, but rarely severe, anaemia in infants. However, a medium-term impact on haematological parameters of antiretroviral-exposed infants has been reported, with small but persistent reductions in levels of neutrophils, platelets and lymphocytes in children up to 8 years of age; the clinical significance of this remains uncertain. To date, there is no evidence to suggest that exposure to antiretroviral drugs in utero or neonatally is associated with an increased risk of childhood cancer, but the potential for mutagenic and carcinogenic effects at older ages cannot be excluded. Nucleoside analogue-related mitochondrial toxicity is well recognised from studies in non-pregnant individuals, whilst animal studies have provided evidence of mitochondrial toxicity resulting from in utero antiretroviral exposure. Clinically evident mitochondrial disease in children with antiretroviral exposure has only been described in Europe, with an estimated 18-month incidence of ‘established’ mitochondrial dysfunction of 0.26% among exposed children.

Regarding pregnancy-related adverse effects, increased risks of prematurity, pre-eclampsia and gestational diabetes mellitus have been reported by a variety of observational studies with varying strengths of evidence and with conflicting results. Based on current knowledge, the immense benefits of antiretroviral prophylaxis in prevention of mother-to-child transmission far outweigh the potential for adverse effects. However, these potential adverse effects require further and longer term monitoring because they are likely to be rare and to occur later in childhood.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. UNAIDS. Report on the Global AIDS Epidemic, 2006. Geneva: UNAIDS, 2006

  2. Thorne C, Newell ML. Mother-to-child transmission of HIV infection and its prevention. Curr HIV Res 2003; 1(4): 447–62

    Article  PubMed  CAS  Google Scholar 

  3. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Eng J Med 1999; 341: 394–402

    Article  CAS  Google Scholar 

  4. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999; 353: 773–80

    Article  PubMed  CAS  Google Scholar 

  5. Cooper ER, Charurat M, Mofenson LM, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29: 484–94

    PubMed  CAS  Google Scholar 

  6. European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 1999; 13: 1377–85

    Google Scholar 

  7. European Collaborative Study. Mother-to-child transmission of HIV Infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40 (3): 458–65

    Google Scholar 

  8. Mirochnick M. Antiretroviral pharmacology in pregnant women and their newborns. Ann N Y Acad Sci 2000; 918: 287–97

    Article  PubMed  CAS  Google Scholar 

  9. Public Health Service Task Force. Safety and toxicity of individual antiretroviral agents in pregnancy: supplement to PHSTF recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States 2006 [online]. Available from URL: http:aidsinfo.nih.gov [Accessed 2006 Oct 17]

  10. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomised trial. JAMA 2002; 288: 189–98

    Article  PubMed  CAS  Google Scholar 

  11. Marzolini C, Rudin C, Decosterd LA, et al. Transplacental passage of protease inhibitors at delivery. AIDS 2002; 16: 889–93

    Article  PubMed  CAS  Google Scholar 

  12. Vitayasai V, Moyle G, Supajatura V, et al. Safety and effiacy of saquinavir soft-gelatin capsules and zidovudine and optional lamivudine in pregnancy and the prevention of vertical HIV transmission. J Acquir Immune Defic Syndr 2002; 30(4): 410–2

    Google Scholar 

  13. Chappuy H, Treluyer JM, Rey E, et al. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol 2004; 191(2): 558–62

    Article  PubMed  CAS  Google Scholar 

  14. Forestier F, de Renty P, Peytavin G, et al. Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model. Am J Obstet Gynecol 2001; 185(1): 178–81

    Article  PubMed  CAS  Google Scholar 

  15. Casey BM, Bawdon RE. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. Am J Obstet Gynecol 1998; 179(3 Pt 1): 758–61

    Article  PubMed  CAS  Google Scholar 

  16. Bristol-Myers Squibb Company. Important change in Sustiva (efavirenz) package insert: change from category C to D, March 2005 [online]. Available from URL: http://www.fda.gov/medwatch/SAFETY/2005/Sustiva_DHCPletter-061005.pdf [Accessed 2006 Oct 24]

  17. Connor EM, Sperling RS, Gelber RD, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Eng J Med 1994; 331: 1173–80

    Article  CAS  Google Scholar 

  18. Mayaux MJ, Teglas JP, Mandelbrot L, et al. Acceptability and impact of zidovudine prevention on mother-to-child HIV-1 transmission in France. J Pediatr 1997; 131: 857–62

    Article  PubMed  CAS  Google Scholar 

  19. European Collaborative Study. Therapeutic and other interventions to reduce the risk of mother-to-child transmission of HIV-1 in Europe. Br J Obstet Gynaecol 1998; 105: 704–9

    Google Scholar 

  20. Centers for Disease Control and Prevention. Enhanced perinatal surveillance: United States, 1999-2001. 4 ed. Atlanta (GA): US Department of Health and Human Sciences, 2004 [online]. Available from URL: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/2004spec_no4/default.htm [Accessed 2006 Oct 24]

  21. Cooper ER, Nugent RP, Pitt J, et al. After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical tranmission of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis 1996; 174: 1207–11

    Article  PubMed  CAS  Google Scholar 

  22. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants in resource-limited settings: towards universal access. Recommendations for a public health approach [online]. Available from URL: http://www.who.int/hiv/pub/guidelines/pmtct/en/index.html [Accessed 2006 Oct 17]

  23. British HIV Association. Guidelines for the management of HIV infection in pregnant women and the prevention of mother- to-child transmission of HIV [online]. Available from URL: http://www.bhiva.org [Accessed 2006 Oct 17]

  24. European Collaborative Study. The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West. AIDS 2006; 20: 1419–27

    Google Scholar 

  25. Scotland GS, Van Teijlingen ER, Van Der PM, et al. A review of studies assessing the costs and consequences of interventions to reduce mother-to-child HIV transmission in sub-Saharan Africa. AIDS 2003; 17(7): 1045–52

    Article  PubMed  Google Scholar 

  26. McIntyre JA. Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV. Expert Opin Pharmacother 2006; 7(6): 677–85

    Article  PubMed  CAS  Google Scholar 

  27. Jourdain G, Ngo-Giang Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Eng J Med 2004; 351: 229–40

    Article  CAS  Google Scholar 

  28. Eshleman SH, Guay LA, Mwatha A, et al. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6–8 weeks after single-dose nvp prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses 2004; 20(6): 595–9

    Article  PubMed  CAS  Google Scholar 

  29. McIntyre JA, Martinson N, Investigators for trial 1413, et al. Addition of short course combivir (CBV) to single dose viramune (sdNVP) for prevention of mother-to-child transmission (MTCT) of HIV-1 can significantly decrease the subsequent development of maternal NNRTI-resistant virus. XV International AIDS conference; 2004 Jul 11-16; Bangkok

  30. Chaix ML, Ekouevi DK, Rouet F, et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d’Ivoire. J Infect Dis 2006; 193(4): 482–7

    Article  PubMed  CAS  Google Scholar 

  31. Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002; 16(2): 299–300

    Article  PubMed  Google Scholar 

  32. De Santis M, Carducci B, De Santis L, et al. Periconceptional exposure to Efavirenz and neural tube defects [letter]. Arch Intern Med 2002; 162: 355

    Article  PubMed  Google Scholar 

  33. Nightingale SL. From the Food and Drug Administration. JAMA 1998; 280(17): 1472

    Article  PubMed  CAS  Google Scholar 

  34. Watts DH. Management of human immunodeficiency virus infection in pregnancy. N Eng J Med 2002; 346: 1879–91

    Article  CAS  Google Scholar 

  35. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 380–7

    Google Scholar 

  36. European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS 2001; 15: 761–70

    Google Scholar 

  37. Sperling RS, Shapiro DE, McSherry GD, et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 study. AIDS 1998; 12: 1805–13

    Article  PubMed  CAS  Google Scholar 

  38. European Collaborative Study. Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIVinfected women? J Acquir Immune Defic Syndr 2005; 40 (1): 116–8

    Google Scholar 

  39. Townsend CL, Tookey PA, Cortina-Borja M, et al. Antiretroviral therapy and congenital abnormalities in infants born to HIV-1-infected women in the United Kingdom and Ireland, 1990 to 2003. J Acquir Immune Defic Syndr 2006; 42(1): 91–4

    Article  PubMed  Google Scholar 

  40. Antiretroviral Pregnancy Registry, 2005 [online]. Available from URL http://www.apregistry.com [Accessed 2007 Jan 25]

  41. Taha TE, Kumwenda NI, Gibbons A, et al. Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants. AIDS 2002; 16(6): 851–8

    Article  PubMed  CAS  Google Scholar 

  42. Wiktor SZ, Ekpini ER, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d’Ivoire: a randomised trial. Lancet 1999; 353: 781–5

    Article  PubMed  CAS  Google Scholar 

  43. Shapiro RL, Ndung’u T, Lockman S, et al. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breastmilk. J Infect Dis 2005; 192: 713–9

    Article  PubMed  CAS  Google Scholar 

  44. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, et al. Perinatal antiretroviral treatment and hematopoiesis in HIV — uninfected infants. AIDS 2003; 17(14): 2053–61

    Article  PubMed  Google Scholar 

  45. European Collaborative Study. Levels and patterns of neutrophil cell counts over the first 8 years of life in children of HIV-1 infected mothers. AIDS 2004; 18: 2009–17

    Google Scholar 

  46. European Collaborative Study. Maternal factors and levels of total lymphocyte, CD4 and CD8 counts in uninfected children born to HIV-1-infected mothers. AIDS 2005; 19: 1071–9

    Google Scholar 

  47. Bunders MJ, Bekker V, Scherpbier HJ, et al. Haematological parameters of HIV-1-uninfected infants born to HIV-1-infected mothers. Acta Paediatr 2005; 94(11): 1571–7

    Article  PubMed  Google Scholar 

  48. Toltzis P, Marz CM, Kleinman N, et al. Zidovudine-associated embryonic toxicity in mice. J Infect Dis 1991; 163: 1212–8

    Article  PubMed  CAS  Google Scholar 

  49. Olivero OA, Fernandez JJ, Antiochos BB, et al. Transplacental genotoxicity in combined antiretroviral nucleoside therapy in Erythrocebus patas monkeys. J AIDS 2002; 29(4): 323–9

    CAS  Google Scholar 

  50. Hanson IC, Antonelli A, Sperling RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 463–7

    Article  PubMed  CAS  Google Scholar 

  51. Culnane M, Fowler MG, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA 1999; 13(2): 151–7

    Article  Google Scholar 

  52. Brogly S, Williams P, Seage GR, et al. In utero nucleoside reverse transcriptase inhibitor exposure and cancer in HIV-uninfected children: an update from the pediatric AIDS clinical trials group 219 and 219C cohorts. J Acquir Immune Defic Syndr 2006; 41(4): 535–6

    Article  PubMed  Google Scholar 

  53. Oleske JM. Long-term outcomes in infants born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 353

    Article  PubMed  Google Scholar 

  54. Poirier MC, Olivero OA, Walker DM, et al. Perinatal genotoxicity and carcinogenicity of antiretroviral nucleoside analog drugs. Toxicol Appl Pharmacol 2004; 199(2): 151–61

    Article  PubMed  CAS  Google Scholar 

  55. Hankin C. Exposure to antiretroviral therapy in uninfected children born to HIV-infected women in Europe. London: University of London, PhD thesis, 2006

    Google Scholar 

  56. Gerschenson M, Erhart SW, Paik CY, et al. Fetal mitochondrial heart and skeletal muscle damage in Erythrocebus patas monkeys exposed in utero to 3′-azido-3′-deoxythymidine. AIDS Res Hum Retroviruses 2000; 16(7): 635–44

    Article  PubMed  CAS  Google Scholar 

  57. Ewings EL, Gerschenson M, St Claire MC, et al. Genotoxic and functional consequences of transplacental zidovudine exposure in fetal monkey brain mitochondria. J Acquir Immune Defic Syndr] 2000; 24(2): 100–5

    CAS  Google Scholar 

  58. Chan SS, Santos JH, Meyer JN, et al. Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination. Environ Mol Mutagen 2006, Epub 2006 Jan 4

    Google Scholar 

  59. Divi RL, Walker V, Wade N, et al. Mitochrondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir. AIDS 2004; 18(5): 1013–21

    Article  PubMed  CAS  Google Scholar 

  60. Shiramizu B, Shikuma KM, Kamemoto L, et al. Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr 2003; 32(4): 370–4

    Article  PubMed  CAS  Google Scholar 

  61. Divi RL, Leonard SL, Kuo MM, et al. Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity. Environ Mol Mutagen 2006, Epub 2006 Mar

    Google Scholar 

  62. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084–9

    Article  PubMed  CAS  Google Scholar 

  63. French Perinatal Cohort Study. Risk of early febrile seizure with perinatal exposure to nucleoside analogues. Lancet 2002; 359: 583–4

    Google Scholar 

  64. Noguera A, Fortuny C, Munoz-Almagro C, et al. Hyperlactatemia in human immunodeficiency virusun-infected infants who are exposed to antiretrovirals. Pediatrics 2004; 114(5): e598–603

    Article  PubMed  Google Scholar 

  65. Tovo PA, Chiapello N, Gabiano C, et al. Zidovudine administration during pregnancy and mitochondrial disease in the offspring. Antivir Ther 2005; 10(6): 697–9

    PubMed  CAS  Google Scholar 

  66. Lindegren ML, Rhodes PH, Gordon L, et al. Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann N Y Acad Sci 2000; 918: 222–35

    Article  PubMed  CAS  Google Scholar 

  67. Mofenson LM, Munderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. AIDS 2002; 30(2): 200–15

    CAS  Google Scholar 

  68. Giaquinto C, Rampon O, Torresan S, et al. Lactic acid levels in infants exposed to antiretrovirals during fetal life [abstract no. 941] 11th Conference on Retroviruses and Opportunitistic Infections, 2004 Feb 8-11; San Francisco (CA)

  69. Giaquinto C, De Romeo A, Giacomet V, et al. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS 2001; 15(8): 1074–5

    Article  PubMed  CAS  Google Scholar 

  70. Alimenti A, Burdge DR, Ogilvie GS, et al. Lactic acidemia in HIV-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003; 22(9): 782–9

    Article  PubMed  Google Scholar 

  71. Garcia Fructuoso MT, Fortuny C, Ramos JT, et al. Perinatally exposed children to antiretrovirals in Spain: a multicentre cohort study [abstract B12155]. XIV International AIDS Conference; 2002 Jul; Barcelona

  72. Ekouevi DK, Toure R, Becquet R, et al. Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hepatites Virales 1209 study, Abidjan, Ivory Coast. Pediatrics 2006; 118(4): e1071–7

    Article  PubMed  Google Scholar 

  73. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 1998; 12: F241–7

    Article  PubMed  CAS  Google Scholar 

  74. European Collaborative Study and the Swiss Mother+Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14: 2913–20

    Google Scholar 

  75. European Collaborative Study. Increased risk of adverse pregnancy outcomes in HAART-treated HIV-infected women in Europe. AIDS 2004; 17: 2337–9

    Google Scholar 

  76. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Eng J Med 2002; 346(24): 1863–70

    Article  Google Scholar 

  77. Cotter AM, Garcia AG, Duthely ML, et al. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006; 193(9): 1195–201

    Article  PubMed  CAS  Google Scholar 

  78. Tuomala RE, Yawetz S. Protease inhibitor use during pregnancy: is there an obstetrical risk? J Infect Dis 2006; 193(9): 1191–4

    Article  PubMed  CAS  Google Scholar 

  79. Fiore S, Newell ML, Trabattoni D, et al. Antiretroviral therapyassociated modulation of Th-1 and Th-2 immune responses in HIV-infected pregnant women. J Repro Immunol 2006; 70: 143–50

    Article  CAS  Google Scholar 

  80. Wimalasundera RC, Larbalestier N, Smith JH, et al. Pre-eclamsia, antiretroviral therapy, and immune reconstitution. Lancet 2002; 360: 1152–4

    Article  PubMed  CAS  Google Scholar 

  81. Stratton P, Tuomala RE, Abboud R, et al. Obstetric and newborn outcomes in a cohort of HIV-infected pregnant women: a report of the women and infants transmission study. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20(2): 179–86

    Article  PubMed  CAS  Google Scholar 

  82. Suy A, Martinez E, Coll O, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006; 20(1): 59–66

    Article  PubMed  Google Scholar 

  83. Watts DH, Balasubramanian R, Maupin RT, et al. Maternal toxicity and pregnancy complications in HIV-infected women receiving antiretroviral therapy: an analysis of the PACTG 316 Study. Am J Obstet Gynecol 2004; 190: 506–16

    Article  PubMed  CAS  Google Scholar 

  84. Chmait R, Franklin P, Spector SA, et al. Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance. J Perinatol 2002; 22: 370–3

    Article  PubMed  Google Scholar 

  85. Tang JH, Sheffield JS, Grimes J, et al. Effect of protease inhibitor therapy on glucose intolerance in pregnancy. Obstet Gynecol 2006; 107(5): 1115–9

    Article  PubMed  CAS  Google Scholar 

  86. El Beitune P, Duarte G, Foss MC, et al. Effect of antiretroviral agents on carbohydrate metabolism in HIV-1 infected pregnant women. Diabetes Metab Res Rev 2006; 22(1): 59–63

    Article  PubMed  Google Scholar 

  87. Hitti J, Andersen J, McComsey G, et al. Effect of protease inhibitor-based ART on glucose tolerance in pregnancy: ACTG A5084 [abstract 711]. Conference on Retroviruses and Opportunistic Infections; 2006 Feb; Denver (CO)

  88. Boulassel MR, Morales R, Murphy T, et al. Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons. J Med Virol 2006; 78(9): 1158–63

    Article  PubMed  CAS  Google Scholar 

  89. Food and Drug Administration. Important drug warning - zerit and videx [online]. Available from URL: http://www.fda.gov/medwatch/safety/2001/zerit&videx_letter.htm January 5 2001 [Accessed 2006 Oct 17]

  90. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Inf 2002; 78: 58–958-9

    Article  CAS  Google Scholar 

  91. Mandelbrot L, Kermarrec N, Marcollet A, et al. Case report: nucleoside analogue-induced lactic acidosis in the third trimester of pregnancy. AIDS 2003; 17: 272–3

    Article  PubMed  Google Scholar 

  92. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2004; 356(9239): 1423–30

    Article  Google Scholar 

  93. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191: 825–9

    Article  PubMed  CAS  Google Scholar 

  94. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, et al. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001; 15(14): 1843–8

    Article  PubMed  CAS  Google Scholar 

  95. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35(5): 538–9

    Article  PubMed  Google Scholar 

  96. Stern JO, Robinson PA, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34Suppl. 1: S21–33

    Article  PubMed  CAS  Google Scholar 

  97. Lyons F, Hopkins S, Kelleher B, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006; 7(4): 255–60

    Article  PubMed  CAS  Google Scholar 

  98. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy. J Acquir Immune Defic Syndr 2004; 36(3): 772–6

    Article  PubMed  CAS  Google Scholar 

  99. Joao EC, Calvet GA, Menezes JA, et al. Evaluation of nevirapine toxicity in a cohort of HIV-1 infected pregnant women [abstract ThOrB1354]. XV International AIDS conference, 2004 Jul 11-16; Bangkok

  100. Gonzalez-Garcia A, Fernandez MI, Cotter A. Nevirapine toxicity in the obstetrical population when used in combination with other antiretrovirals [abstract WePeB5918]. XV International AIDS conference, 2004 Jul 11-16; Bangkok

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, 30 Guilford Street, London, WC1N 1EH, UK

    Claire Thorne & Marie-Louise Newell

Authors
  1. Claire Thorne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marie-Louise Newell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claire Thorne.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thorne, C., Newell, ML. Safety of Agents Used to Prevent Mother-to-Child Transmission of HIV. Drug-Safety 30, 203–213 (2007). https://doi.org/10.2165/00002018-200730030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200730030-00004

Keywords

Search

Navigation